Compounds > tipifarnib
Page last updated: 2024-09-04

tipifarnib and Neutropenia

tipifarnib has been researched along with Neutropenia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alexeeva, JA; Bessems, A; Beutel, G; Bordessoule, D; Brandwein, JM; Burnett, AK; De Porre, P; Dombret, H; Golenkov, AK; Harousseau, JL; Howes, AJ; Jedrzejczak, WW; Khuageva, NK; Maertens, J; Martinelli, G; Masszi, T; Mollgard, L; Ossenkoppele, GJ; Park, YC; Robak, T; Thomas, X; Tothova, E; Vidriales, MB1
Adjei, AA; Bruzek, L; Erlichman, C; Geyer, S; Hanson, LJ; Hillman, S; Kaufmann, SH; Marks, RS; Mauer, A; Vokes, EE; Wright, JJ1
Dowsett, M; Ellis, P; Hickish, T; Houston, S; Howes, A; Johnston, SR; Kelland, L; Michiels, B; Palmer, P; Perez-Ruixo, JJ; Salter, J1
Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D1
Mardiak, J; Moore, M; Palmer, PA; Perez-Ruixo, JJ; Rosenberg, JE; Sahasrabudhe, D; Seigne, JD; Small, EJ; Vaughn, DJ; von der Maase, H1

Trials

5 trial(s) available for tipifarnib and Neutropenia

ArticleYear
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
    Blood, 2009, Aug-06, Volume: 114, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Neutropenia; Quinolones; Survival Rate; Time Factors

2009
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Anemia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Farnesyltranstransferase; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Neutropenia; Quinolones; Survival

2003
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinolones; Thrombocytopenia; Treatment Outcome

2003
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones

2004
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Cancer, 2005, May-15, Volume: 103, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Diarrhea; Enzyme Inhibitors; Exanthema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quinolones; Remission Induction; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

2005